InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Explore the detailed record of transactions filed by Alexandre Mérieux, Président exécutif de bioMérieux. Director active across 1 companies, notably BIOMERIEUX. Cumulatively, 8 filings have been published. Total volume traded: €81m. The latest transaction was disclosed on 25 March 2025 — Transfert à titre gratuit d'actions. Regulator: AMF. All data is accessible without signup.
Declarations8 total
€2bn2,152,868 shares@ €1,095.164823.2% of flow
Actions de Compagnie Mérieux AllianceHors plateforme de négociation
2025DD1027996·
€2bn2,152,868 shares@ €1,095.164823.2% of flow
Actions de CMAHors plateforme de négociation
2025DD1027997·
€706m778,699 shares@ €906.837533.3% of flow
Actions de Compagnie Mérieux Alliance et de AME HoldingHors plateforme de négociation
2025DD1013673·
€706m778,699 shares@ €906.837533.3% of flow
Actions de Compagnie Mérieux Alliance et de MHC HoldingHors plateforme de négociation
2025DD1013681·
€706m778,699 shares@ €906.837533.3% of flow
Actions de Compagnie Mérieux Alliance et de APC HoldingHors plateforme de négociation
2025DD1013686·
€2bn2,336,097 shares@ €906.837520.8% of flow
Actions de Compagnie Mérieux Alliance, AME Holding, MHC Holding et APCHors plateforme de négociation
2024DD1012649·
€81m58,148 shares@ €1,393.040.62% mcap100.0% of flow
Actions de Compagnie Mérieux AllianceHors plateforme de négociation
2024DD1006251·
Ideal exit: 1 Jul 2025 (T+270)
€1bn870,333 shares@ €1,393.0411.9% of flow
Actions de Compagnie Mérieux AllianceHors plateforme de négociation
2024DD1006257·
8 of 8 declarations
About Alexandre Mérieux
Alexandre Mérieux is a key figure in the governance of bioMérieux, the French specialist in in vitro diagnostics. He currently serves as Executive Chairman of bioMérieux, after having previously held the roles of Chief Executive Officer and, earlier, Chairman and CEO. Following the governance changes implemented in July 2023, he retained a strategic leadership role on the Board, while day-to-day management was entrusted to Pierre Boulud. He is also a long-standing board member of bioMérieux. He holds a degree in biology from Lyon I University and a diploma from HEC Montréal. Before joining bioMérieux, he spent 1999 to 2004 in marketing roles at Silliker Group, working in the United States and Europe, and later as a marketing and business unit director in France. He joined bioMérieux in 2005 as Executive Vice President, Industrial Microbiology. He then led the Industrial Microbiology business from 2005 to 2011, and the Microbiology division from 2011 to 2014. He was appointed Chief Executive Officer in 2014 and became Chairman and CEO in December 2017. His career reflects the continuity of the Mérieux family’s industrial and scientific legacy, but also a progression built on operational management experience. At bioMérieux, he has overseen the strengthening of microbiology activities, the development of higher-value diagnostic solutions, and the execution of an international growth strategy. During his tenure, the company continued to invest in innovation, commercial expansion, and industrial capabilities in a healthcare environment undergoing rapid change. A notable moment in his leadership was the 2023 governance reshaping, designed to separate strategic oversight from executive management more clearly.
